Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Drug Profile

Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Alternative Names: Autologous-cultured-fibroblasts-RepliCel; NBDS fibroblast therapy - RepliCel; RCS-01; RCT-01; RCT-A-01; RCT-P-01; RepliCel Tendon-01; Skin aging therapy - RepliCel; Skin rejuvenation - RepliCel; Tendon repair - RepliCel

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RepliCel Life Sciences; Royal National Orthopaedic Hospital; Royal University Hospital
  • Class Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Tendon injuries
  • Phase I Skin aging

Most Recent Events

  • 25 Jan 2018 RepliCel plans a phase II trial of RCS 01 in Skin aging in Europe in 2018
  • 25 Jan 2018 RepliCel plans a phase II trial of RCT 01 for Tendon injuries in in Hong Kong and Mainland China in 2018
  • 16 Jan 2018 RCT-01 and RCS-01 licensed to YOFOTO (China) Health Industry in Greater China, including Hong Kong, Macau and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top